13F Holdings
中文EN

LGND LIGAND PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 886163 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.0%
TTM net income YoY5.9%
TTM EPS YoY9.7%
Revenue 3-yr CAGR18.2%
Net income 3-yr CAGR46.2%

Margins

Gross margin—
Operating margin9.5%
Net margin20.3%
FCF margin35.7%
EBITDA margin23.2%

Returns

ROE5.4%
ROA2.8%
ROIC (approx.)1.4%
Asset turnover0.14x

Leverage & solvency

Liabilities / assets57.0%
Debt / equity1.17x
Current ratio1.22x
Interest coverage2.94x

Cash quality & payout

Operating cash flow / net income1.77x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$268.09M$167.13M$131.31M$196.25M$241.54M
R&D expense$81.18M$21.43M$24.54M$36.08M$32.10M
SG&A expense$92.45M$78.65M$52.79M$70.06M$46.79M
Operating income$41.00M-$22.61M$11.94M$3.04M$103.85M
Interest expense$4.71M$3.04M$656,000$1.80M$19.62M
Pretax income$158.96M$2.52M$63.66M$36.01M$72.20M
Income tax$34.51M$6.55M$9.84M$41.23M-$4.15M
Net income$124.45M-$4.03M$52.15M-$33.36M$57.14M
EBITDA$74.78M$12.63M$48.46M$54.57M$154.92M
EPS (basic)6.44-0.223.02-1.983.44
EPS (diluted)6.13-0.222.94-1.983.31
Weighted avg. shares (diluted)20.29M18.29M17.76M16.87M17.25M
Balance sheet
Cash & equivalents$174.93M$72.31M$22.95M$45.01M$19.52M
Short-term investments$558.59M$183.86M$147.35M$166.86M$321.59M
Receivables$59.60M$38.38M$32.92M$30.42M$85.45M
Inventory$9.13M$14.11M$23.97M$13.29M$27.33M
Current assets$832.27M$331.56M$237.43M$263.60M$464.75M
PP&E, net$3.57M$15.13M$15.61M$12.48M$13.19M
Goodwill$101.54M$105.25M$103.37M$0$105.67M
Intangibles$225.44M$266.65M$299.61M$342.45M$376.69M
Total assets$1.56B$941.77M$787.22M$762.67M$1.30B
Current liabilities$37.45M$37.11M$16.78M$98.81M$41.66M
Long-term debt$446.19M$0———
Total debt$446.19M$0———
Total liabilities$543.42M$111.33M$86.30M$165.18M$476.43M
Shareholders' equity$1.02B$830.44M$700.91M$597.49M$821.16M
Net debt$271.26M-$72.31M———
Shares outstanding19.77M19.11M17.56M16.95M16.77M
Cash flow statement
Operating cash flow$49.36M$97.05M$49.58M$137.85M$78.80M
Capital expenditure$452,000$1.82M$3.52M$17.92M$8.76M
Free cash flow$48.91M$95.23M$46.06M$119.93M$70.04M
Investing cash flow-$377.32M-$143.66M-$11.68M$163.62M$30.52M
Financing cash flow$428.22M$97.14M-$59.95M-$275.99M-$137.76M
Depreciation & amortization$33.77M$35.24M$36.52M$51.53M$51.07M
Stock-based compensation$46.85M$41.09M$25.74M$60.28M$38.78M
Share buybacks$15.00M$0$0$0$0

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.